source
- FDA grants rapid approval to Revolution Medicines' pancreatic cancer drug RasonqueFDA approved Revolution Medicines' pancreatic cancer therapy Rasonque, just over a month after submission using a priority review voucher. The drug, formerly known as daraxonrasib, is for patients…
- Akeso CEO looks beyond lung cancer with biliary tract win, counters ivonescimab debateFresh off a phase 3 win in biliary tract cancer, Akeso CEO Michelle Xia, Ph.D., is touting the PD-1xVEGF bispecific antibody ivonescimab’s ability beyond non-small cell lung cancer, even as she con…Fierce Biotech · 10h ago↗ source